Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war

Bristol-Myers Squibb 2021-03-25 1:58 pm By Miklos Bolza | Sydney

Please login to bookmark

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au